Alnylam Pharmaceuticals I...

241.97
5.22 (2.20%)
At close: Apr 23, 2025, 3:59 PM
241.89
-0.03%
Pre-market: Apr 24, 2025, 04:23 AM EDT

Alnylam Pharmaceuticals Statistics

Share Statistics

Alnylam Pharmaceuticals has 130.07M shares outstanding. The number of shares has increased by 2.83% in one year.

Shares Outstanding 130.07M
Shares Change (YoY) 2.83%
Shares Change (QoQ) 0.85%
Owned by Institutions (%) 99.99%
Shares Floating 124.35M
Failed to Deliver (FTD) Shares 44
FTD / Avg. Volume < 0.01%

Short Selling Information

The latest short interest is 2.99M, so 2.31% of the outstanding shares have been sold short.

Short Interest 2.99M
Short % of Shares Out 2.31%
Short % of Float 3.06%
Short Ratio (days to cover) 2.55

Valuation Ratios

The PE ratio is -108.78 and the forward PE ratio is 158.79. Alnylam Pharmaceuticals's PEG ratio is 2.82.

PE Ratio -108.78
Forward PE 158.79
PS Ratio 13.46
Forward PS 4.1
PB Ratio 451.03
P/FCF Ratio -710.48
PEG Ratio 2.82
Financial Ratio History

Enterprise Valuation

Currently the Enterprise Value (EV) is not available for Alnylam Pharmaceuticals.

EV / Sales n/a
EV / EBITDA n/a
EV / EBIT n/a
EV / FCF n/a

Financial Position

The company has a current ratio of 2.78, with a Debt / Equity ratio of 19.32.

Current Ratio 2.78
Quick Ratio 2.71
Debt / Equity 19.32
Debt / EBITDA -7.25
Debt / FCF -30.43
Interest Coverage -1.25

Financial Efficiency

Return on Equity is n/a and Return on Invested Capital is n/a.

Return on Equity n/a
Return on Assets n/a
Return on Invested Capital n/a
Revenue Per Employee $1.01M
Profits Per Employee $-124.73K
Employee Count 2,230
Asset Turnover 0.53
Inventory Turnover 4.12

Taxes

Income Tax 99.22M
Effective Tax Rate -55.45%

Stock Price Statistics

The stock price has increased by 68.27% in the last 52 weeks. The beta is 0.3, so Alnylam Pharmaceuticals's price volatility has been higher than the market average.

Beta 0.3
52-Week Price Change 68.27%
50-Day Moving Average 249.54
200-Day Moving Average 258.78
Relative Strength Index (RSI) 48.62
Average Volume (20 Days) 907.85K

Income Statement

In the last 12 months, Alnylam Pharmaceuticals had revenue of 2.25B and earned -278.16M in profits. Earnings per share was -2.16.

Revenue 2.25B
Gross Profit 1.92B
Operating Income -176.88M
Net Income -278.16M
EBITDA -178.85M
EBIT -235.52M
Earnings Per Share (EPS) -2.16
Full Income Statement

Balance Sheet

The company has 127.13M in cash and 1.3B in debt, giving a net cash position of -1.17B.

Cash & Cash Equivalents 127.13M
Total Debt 1.3B
Net Cash -1.17B
Retained Earnings 0
Total Assets 4.24B
Working Capital 2.11B
Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -8.31M and capital expenditures -34.28M, giving a free cash flow of -42.59M.

Operating Cash Flow -8.31M
Capital Expenditures -34.28M
Free Cash Flow -42.59M
FCF Per Share -0.33
Full Cash Flow Statement

Margins

Gross margin is 85.62%, with operating and profit margins of -7.87% and -12.37%.

Gross Margin 85.62%
Operating Margin -7.87%
Pretax Margin -7.96%
Profit Margin -12.37%
EBITDA Margin -7.95%
EBIT Margin -7.87%
FCF Margin -1.89%

Dividends & Yields

ALNY does not appear to pay any dividends at this time.

Dividend Per Share n/a
Dividend Yield n/a
Dividend Growth (YoY) n/a
Payout Ratio n/a
Earnings Yield n/a
FCF Yield n/a
Dividend Details

Analyst Forecast

The average price target for ALNY is $322.5, which is 33.3% higher than the current price. The consensus rating is "Buy".

Price Target $322.5
Price Target Difference 33.3%
Analyst Consensus Buy
Analyst Count 24
Stock Forecasts

Scores

Altman Z-Score 2.98
Piotroski F-Score 4